Arindam Bose Email & Phone Number

Greater Boston Area

• Leading spatial proteomics research for biomarker development and validation.• Integrating tissue multiplexing with artificial intelligence to understand protein expression patterns and influence on tumor micro-environment.• Exploring next generation discovery projects by combining digital pathology, spatial statistics and machine learning.• Establishing strategic collaboration with industry and academic partners.

Greater Boston Area

• Lead investigator managed three-dimensional tissue research team.• Drug discovery co-Lead of targeting DNA Damage Response (DDR) pathways with particular focus on next generation DDR inhibitors.• Established genetically and functionally characterized organoid biobanks that functionally represent patients. Assessed predictive potential of organoid technology. Studied phenotypic and molecular heterogeneity of patient’s tumor in a dish.• Participated in NCI and industry sponsored… Show more • Lead investigator managed three-dimensional tissue research team.• Drug discovery co-Lead of targeting DNA Damage Response (DDR) pathways with particular focus on next generation DDR inhibitors.• Established genetically and functionally characterized organoid biobanks that functionally represent patients. Assessed predictive potential of organoid technology. Studied phenotypic and molecular heterogeneity of patient’s tumor in a dish.• Participated in NCI and industry sponsored clinical trials to predict therapy outcome using organoid platform and correlate patient response. Applied new combination opportunities with standard of care. Utilized high throughput screening technologies of FDA-approved drug libraries to identify/repurpose lead compounds. Show less

Greater Boston Area

Executed in vitro, ex vivo and in vivo experiments in the discovery and target validation of novel biomarkers for anticancer chemo/radio therapy. Design, development, and validation of novel functional assays for tumor profiling.

Greater Boston Area

• Implemented organoid platform for testing and development of new therapeutic approaches in pre-clinical and clinical settings. Combined functional assays and multi-omics profiling to generate targeted therapies. • Developed novel precision medicine strategies by stratifying patients’ population based on functional screenings. Identified responders and non-responders. Provided molecularly tailored therapy options by selecting right drug for right patient.

Greater Boston Area

• Evaluated how fresh tissues from tumor biopsy and debulking surgery respond to novel functional assays in ex vivo environment. • Explored patient derived xenograft models for best therapeutic approaches. • Performed automated drug-screening to model clinically applied therapeutic regimens.• Investigated new translational pathways to treat pancreatic ductal adenocarcinoma. • Mentored and trained postdocs and students.

Pittsburgh

• Analyzed nucleotide excision repair (NER) pathways in telomere to bridge the gap in existing knowledge about DNA damage repair in telomeres. • Performed CRISPR screens to discover new synthetic lethal pathways.

Pittsburgh, Pennsylvania

• Identified telomerase activity in presence of oxidative DNA lesions in telomeric sequence and in the nucleotide pool to understand dysfunctional redox regulation for targeting cancer. • Invented the non-canonical role of translesion synthesis polymerases in Alternative Lengthening of Telomeres (ALT) pathway for establishing ALT based intervention therapies.

Connecticut

• Studied mutagenic signature and neoplastic potential of dietary carcinogens, environmental pollutants, and tobacco smoke.• Investigated the mechanism of chemotherapeutic resistance of antitumor antibiotics. • Conducted lectures and supervised research laboratories for undergraduate courses.

Fellow, Molecular Oncology

Doctor Of Philosophy (Ph.D.), Biochemistry And Molecular Biology